Pharmacokinetics and Biodistribution of 111In- and 177Lu-Labeled J591 Antibody Specific for Prostate-Specific Membrane Antigen: Prediction of 90Y-J591 Radiation Dosimetry Based on 111In or 177Lu?
Shankar Vallabhajosula, PhD1,
Ichei Kuji, MD1,
Klaus A. Hamacher, PhD1,
Shota Konishi, MD1,
Lale Kostakoglu, MD1,
Paresh A. Kothari, PhD1,
Mathew I. Milowski, MD2,3,
David M. Nanus, MD2,3,
Neil H. Bander, MD3 and
Stanley J. Goldsmith, MD1
1 Division of Nuclear Medicine, Department of Radiology, New York Presbyterian Hospital–Weill Medical College of Cornell University, New York, New York
2 Division of Hematology and Medical Oncology, New York Presbyterian Hospital–Weill Medical College of Cornell University, New York, New York
3 Laboratory of Urological Oncology, Department of Urology, New York Presbyterian Hospital–Weill Medical College of Cornell University, New York, New York
View larger version (14K):
[in a new window]
|
FIGURE 1. Urinary excretion of 111In- and 177Lu-labeled J591 mAb over 72-h period from time of administration to patients.
|
|
View larger version (80K):
[in a new window]
|
FIGURE 2. Whole-body images of 111In-J591 and 177Lu-J591 mAb on day 0 (A) and day 6 (B) after administration to 2 different patients.
|
|
View larger version (17K):
[in a new window]
|
FIGURE 3. Whole-body (WB) clearance and liver uptake and washout kinetics of 111In-J591 and 177Lu-J591 mAb from time of administration to patients.
|
|
View larger version (51K):
[in a new window]
|
FIGURE 4. Whole-body images of 99mTc-methylene diphosphonate (A) and 177Lu-J591 mAb (B) in patient with metastatic prostate cancer. 177Lu images obtained on day 7 show significant localization of radiolabeled J591 mAb in most lesions identified on bone scan (A).
|
|
Copyright © 2005 by the Society of Nuclear Medicine.
